Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(18):1326; doi:10.1093/jnci/dji326
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Steimle, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steimle, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Critics Question BRCA2 Patent Decision in Europe

Sabine Steimle

The first 10% of the full text of this article appears below.

The European Patent Office (EPO) announced its decision in late June to uphold an amended form of a BRCA2 patent licensed to Myriad Genetics, giving the company exclusive rights to test for a particular nucleic acid mutation on the BRCA2 gene that is associated with a predisposition to breast cancer in Ashkenazi Jewish women. Opponents of the patent—including genetics societies and breast cancer organizations across Europe—have criticized the ruling as discriminatory.

In clinical practice, the ruling will mean that women who wish to undergo genetic . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?